MAM
PMVP icon

Martingale Asset Management’s PMV Pharmaceuticals PMVP Stock Holding History

Martingale Asset Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,296
Closed -$180K – 835
2023
Q3 		$180K Buy
29,296
+8,000
+38% +$55K ﹤0.01% 757
2023
Q2 		$133K Buy
21,296
+20
+0.1% +$105 ﹤0.01% 783
2023
Q1 		$101K Hold
21,276
– – ﹤0.01% 805
2022
Q4 		$185K Hold
21,276
– – ﹤0.01% 801
2022
Q3 		$254K Buy
21,276
+1,494
+8% +$21.6K 0.01% 741
2022
Q2 		$282K Buy
+19,782
New +$288K 0.01% 745

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Martingale Asset Management's PMVP Position: Q4 2023 in Review

Martingale Asset Management sold out of PMV Pharmaceuticals (PMVP) in Q4 2023, closing a stake of 29,296 shares — an estimated $180K sold.

Martingale Asset Management first reported a position in PMVP in Q2 2022 and held it in 6 quarters. The position peaked at $282K in Q2 2022. 98 funds tracked by Wall St. Rank hold PMVP as of Q4 2023.

  • Martingale Asset Management reported no remaining PMV Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Martingale Asset Management sold 29,296 PMV Pharmaceuticals shares in Q4 2023, an estimated $180K.
  • Martingale Asset Management first reported a position in PMV Pharmaceuticals in Q2 2022 and held it in 6 quarters.
  • Martingale Asset Management's PMV Pharmaceuticals position peaked at $282K in Q2 2022.
  • 98 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2023.

Based on Martingale Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.